Challenges in the development of glaucoma neuroprotection therapy

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Glaucoma, a disease of the optic nerve and retina, causes blindness in millions of people worldwide. Currently available therapies for this disease only attempt to reduce intraocular pressure, the major risk factor, without addressing the associated optic neuropathy and retinopathy. Development of glaucoma neuroprotective treatment is therefore a pressing unmet medical need. Unfortunately, many challenges hinder this effort, including an incomplete understanding of the mechanism of pathogenesis, leading to uncertain therapeutic targets and confounded by not yet validated preclinical models. Most importantly, with slow disease progression and a less than ideal endpoint measurement method, clinical trials are necessarily large, lengthy, expensive and, to many, prohibitive. No easy solution is available to overcome these challenges. Increased commitment to basic mechanistic research is an essential foundation for dealing with this problem. Innovations in clinical trials with novel surrogate endpoints, nontraditional study designs and the use of surrogate diseases might shorten the study time, reduce the patient sample size and consequently lower the budgetary hurdle for the development of new therapies.

Original languageEnglish
Pages (from-to)253-260
Number of pages8
JournalCell and Tissue Research
Volume353
Issue number2
DOIs
StatePublished - 1 Aug 2013

Fingerprint

Glaucoma
Optic Nerve Diseases
Clinical Trials
Blindness
Therapeutics
Intraocular Pressure
Sample Size
Disease Progression
Retina
Biomarkers
Neuroprotection
Research

Keywords

  • Glaucoma
  • Neuroprotection
  • Optic neuropathy
  • Retinopathy
  • Therapy

Cite this

@article{00d9d266438442deac89d7fc58b368c7,
title = "Challenges in the development of glaucoma neuroprotection therapy",
abstract = "Glaucoma, a disease of the optic nerve and retina, causes blindness in millions of people worldwide. Currently available therapies for this disease only attempt to reduce intraocular pressure, the major risk factor, without addressing the associated optic neuropathy and retinopathy. Development of glaucoma neuroprotective treatment is therefore a pressing unmet medical need. Unfortunately, many challenges hinder this effort, including an incomplete understanding of the mechanism of pathogenesis, leading to uncertain therapeutic targets and confounded by not yet validated preclinical models. Most importantly, with slow disease progression and a less than ideal endpoint measurement method, clinical trials are necessarily large, lengthy, expensive and, to many, prohibitive. No easy solution is available to overcome these challenges. Increased commitment to basic mechanistic research is an essential foundation for dealing with this problem. Innovations in clinical trials with novel surrogate endpoints, nontraditional study designs and the use of surrogate diseases might shorten the study time, reduce the patient sample size and consequently lower the budgetary hurdle for the development of new therapies.",
keywords = "Glaucoma, Neuroprotection, Optic neuropathy, Retinopathy, Therapy",
author = "Yang Liu and Iok-Hou Pang",
year = "2013",
month = "8",
day = "1",
doi = "10.1007/s00441-013-1584-z",
language = "English",
volume = "353",
pages = "253--260",
journal = "Cell and Tissue Research",
issn = "0302-766X",
publisher = "Springer Verlag",
number = "2",

}

Challenges in the development of glaucoma neuroprotection therapy. / Liu, Yang; Pang, Iok-Hou.

In: Cell and Tissue Research, Vol. 353, No. 2, 01.08.2013, p. 253-260.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Challenges in the development of glaucoma neuroprotection therapy

AU - Liu, Yang

AU - Pang, Iok-Hou

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Glaucoma, a disease of the optic nerve and retina, causes blindness in millions of people worldwide. Currently available therapies for this disease only attempt to reduce intraocular pressure, the major risk factor, without addressing the associated optic neuropathy and retinopathy. Development of glaucoma neuroprotective treatment is therefore a pressing unmet medical need. Unfortunately, many challenges hinder this effort, including an incomplete understanding of the mechanism of pathogenesis, leading to uncertain therapeutic targets and confounded by not yet validated preclinical models. Most importantly, with slow disease progression and a less than ideal endpoint measurement method, clinical trials are necessarily large, lengthy, expensive and, to many, prohibitive. No easy solution is available to overcome these challenges. Increased commitment to basic mechanistic research is an essential foundation for dealing with this problem. Innovations in clinical trials with novel surrogate endpoints, nontraditional study designs and the use of surrogate diseases might shorten the study time, reduce the patient sample size and consequently lower the budgetary hurdle for the development of new therapies.

AB - Glaucoma, a disease of the optic nerve and retina, causes blindness in millions of people worldwide. Currently available therapies for this disease only attempt to reduce intraocular pressure, the major risk factor, without addressing the associated optic neuropathy and retinopathy. Development of glaucoma neuroprotective treatment is therefore a pressing unmet medical need. Unfortunately, many challenges hinder this effort, including an incomplete understanding of the mechanism of pathogenesis, leading to uncertain therapeutic targets and confounded by not yet validated preclinical models. Most importantly, with slow disease progression and a less than ideal endpoint measurement method, clinical trials are necessarily large, lengthy, expensive and, to many, prohibitive. No easy solution is available to overcome these challenges. Increased commitment to basic mechanistic research is an essential foundation for dealing with this problem. Innovations in clinical trials with novel surrogate endpoints, nontraditional study designs and the use of surrogate diseases might shorten the study time, reduce the patient sample size and consequently lower the budgetary hurdle for the development of new therapies.

KW - Glaucoma

KW - Neuroprotection

KW - Optic neuropathy

KW - Retinopathy

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84880828122&partnerID=8YFLogxK

U2 - 10.1007/s00441-013-1584-z

DO - 10.1007/s00441-013-1584-z

M3 - Review article

C2 - 23474740

AN - SCOPUS:84880828122

VL - 353

SP - 253

EP - 260

JO - Cell and Tissue Research

JF - Cell and Tissue Research

SN - 0302-766X

IS - 2

ER -